{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/665dda1b3ce6480013459039/6a885d5954f87b8876e5c88a?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Will Drug Price Deflation Crimp Retailers' Pharmacy Margins?","description":"<p>Axios reported that Walmart raised its outlook while saying drug price declines pressured pharmacy results. Pharmacy margins are being squeezed by reimbursement terms set by PBMs, generic drug deflation, and the 2024 shift of pharmacy DIR fees to the point of sale. CVS Health and Walgreens Boots Alliance have cited similar headwinds, while Amazon Pharmacy, Mark Cuban Cost Plus Drug Company, and GoodRx are reshaping price transparency and consumer behavior. The Inflation Reduction Act will add Medicare drug price negotiations in 2026 and a $2,000 Part D out-of-pocket cap in 2025, which could shift volumes and reimbursement flows. Rising demand for GLP-1 drugs adds inventory and authorization complexity without guaranteed margin lift. Walmart’s 2024 exit from its health clinics highlights how reimbursement pressures influence strategy, pushing focus back to core pharmacy services and OTC products.</p><p>Learn more on this news by visiting us at: https://greyjournal.net/news/</p><p><br></p><p><br></p>","author_name":"GREY Journal"}